TAMPA, Fla., March 31, 2026 (GLOBE NEWSWIRE)-- Inhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company"), today provided an update on its ongoing pharmacokinetic (PK) clinical program ...

HILLARYS, WA - May 19, 2026 - PRESSADVANTAGE - Bare Skin and Beauty has expanded its professional skincare offerings ...

Formulation Development is a key element in the pharmaceutical development process. There is an increasing trend by companies to outsource not just this service, but an integrated platform of ...

Neurizon received approval for a Phase 1 trial of liquid NUZ-001 for ALS in Australia. This liquid form addresses swallowing difficulties common in ALS patients. NUZ-001 aims to restore autophagy, ...

- Using Ascletis' proprietary Ultra-Long-Acting Platform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly ...

TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies ...

Conventional manufacturing of dosage forms for small molecule drugs in centralized facilities is not well-suited to meet the needs of adaptive clinical trials for early-phase dose escalation and ...

Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with ...

The Indian Council of Medical Research (ICMR)'s multicentric Phase III clinical trial has found that Ayurvedic formulations ...

Hyderabad, India: Asia's leading Discovery Research and Development organization, GVK BIO, announced the extended collaboration with Melbourne, Australia based clinical stage biopharmaceutical company ...